Phase i study of a166, an antibody‒drug conjugate in advanced her2-expressing solid tumours

HIGHLIGHTS

• who: Jian Zhang from the bleeding have published the article: Phase I study of A166, an antibodyu2012drug conjugate in advanced HER2-expressing solid tumours, in the Journal: (JOURNAL) of May/13,/2021
• how: The study was conducted in accordance with the Declaration of Helsinki guidelines and international standards of good clinical practice.
• future: The potential for the bystander killing effect of A166 remains undefined but will be further evaluated in future studies.

SUMMARY

The introduction of HER2-targeted therapies, most notably trastuzumab, pertuzumab, antibody‒drug conjugates (ADCs; e_g, trastuzumab . . .

 



If you want to have access to all the content you need to log in!

Thanks :)

Username or Email

Password

Remember me

Lost your password?

If you don't have an account, you can create one here.